Antares Pharma, Inc. to Initiate Clinical Trial of VIBEX(TM) MTX in First Quarter of 2011

(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced plans to conduct a clinical trial of the Company’s proprietary VIBEX™ MTX product being developed for the treatment of rheumatoid arthritis following clearance of an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA) on December 8, 2010.

MORE ON THIS TOPIC